Immediate Impact
5 from Science/Nature 70 standout
Citing Papers
Natural killer cell therapies
2024 StandoutNature
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial
2023 Standout
Works of Nathan Enas being referenced
Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma
2014
Use of historical control data for assessing treatment effects in clinical trials
2013
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Nathan Enas | 481 | 355 | 147 | 262 | 25 | 1.4k | |
| Mark D. Rothmann | 432 | 430 | 361 | 335 | 44 | 1.7k | |
| Andreas Brandt | 406 | 313 | 119 | 67 | 50 | 1.7k | |
| Jeffrey Skolnik | 513 | 550 | 145 | 91 | 30 | 1.2k | |
| Jiang Liu | 420 | 410 | 68 | 144 | 40 | 1.4k | |
| Dinesh P. de Alwis | 879 | 512 | 66 | 160 | 37 | 1.5k | |
| Brigitte Tranchand | 544 | 269 | 40 | 111 | 50 | 1.2k | |
| Sangbum Choi | 203 | 433 | 69 | 108 | 64 | 1.3k | |
| Ji Lin | 370 | 342 | 40 | 140 | 48 | 1.1k | |
| Nitin Roper | 402 | 445 | 84 | 40 | 44 | 1.2k | |
| Diane Potvin | 179 | 261 | 27 | 173 | 40 | 1.1k |
All Works
Loading papers...